According to a recent LinkedIn post from PictorLabs, the company is drawing attention to how virtual staining technology can be integrated into pathology research workflows. The post emphasizes that virtual staining may serve multiple roles, from upstream quality control and tissue triage to supporting downstream molecular analysis, rather than being limited to a single application.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post also directs readers to an external resource aimed at helping laboratories evaluate where virtual staining might fit into their processes and stresses that the offering is for research use only and not FDA cleared or approved. For investors, this positioning suggests PictorLabs is seeking broader adoption of its digital pathology tools in research settings, which could help build data, user familiarity, and reference customers that may support future commercialization efforts if regulatory pathways are pursued.